Chemistry for Wildlife Health: Drug Discovery and Wildlife Disease in a Science Friday Interview

Overview

In this Science Friday episode, Flora Lichtman speaks with medicinal chemist Tim Cernak about using chemistry to improve wildlife and ecosystem health. The discussion spans the origins of medicines in nature, drug discovery for nonhuman patients, and the potential for chemistry to curb wildlife diseases that threaten species.

• Chemistry as a tool for wildlife health and conservation
• Pebbles the Gila monster and the GLP-1 drug lineage
• Frog chytrid disease and the need for species-specific treatments
• Broader translational value for human medicine and ecology

Overview

The podcast centers on how chemistry can address wildlife disease, a major driver of species decline. Flora Lichtman interviews Dr Tim Cernak, an associate professor of medicinal chemistry at the University of Michigan, about applying drug discovery and pharmacology to wildlife, including amphibians, reptiles, and sea turtles. The conversation emphasizes that diseases such as chytrid fungi and various cancers in wildlife pose existential threats, and that modern chemical tools can help design safer, more targeted interventions for nonhuman patients while offering insights transferable to human health.

Wildlife Diseases and the Role of Chemistry

The discussion frames extinction as a consequence of disease alongside habitat loss and pollution. Chytrid fungi are described as a global amphibian pandemic with a narrow therapeutic window when treated with broad-spectrum antifungals, which may overdose or immunosuppress host species. The podcast highlights the potential for frog- or species-specific drugs designed with the patient in mind, balancing efficacy with ecological safety. The broader question is how to leverage chemical science to restore ecosystem health without unintended consequences.

Case Study: Pebbles the Gila Monster

Pebbles, a Gila monster housed at a wildlife rescue center, became a focal point for how veterinary pharmacology can intersect with conservation. The team traced a connection between Gila monster venom compounds and the development of GLP-1 based medicines for humans, illustrating how natural products inspire therapeutic breakthroughs. When Pebbles faced a parasite infection and imminent euthanasia, researchers adapted treatment by formulating a drug (paromomycin) for a nontraditional patient. The dose scheduling and delivery were innovatively solved by delivering the drug via baby quail, enabling a multi-day course that Pebbles tolerated. After treatment, Pebbles remained in remission for a year and regained weight and coloration, highlighting the potential of animal-centered drug development.

Other Wildlife Interventions

The episode also covers avian influenza as a major wildlife threat and the laboratory work screening cancer drugs and exploring new compounds for sea turtles, whose tumors impair swimming and survival. Tim discusses how sea turtles’ biology, including a different blood–brain barrier profile, shapes drug design and toxicity considerations, while noting that many principles of drug discovery in humans can inform wildlife applications.

Cross-species Learnings and Future Directions

The podcast emphasizes a collaborative, cross-disciplinary approach that blends chemistry, veterinary medicine, and conservation science. It argues that studying wildlife diseases through a chemical lens can uncover pathways and targets relevant to human disease, while also offering practical conservation tools. The discussion also touches on ethical and logistical challenges, such as advancing treatments without causing ecological disruption, and the importance of partnerships with wildlife hospitals and conservation organizations.

Closing Thoughts

The interview frames nature as an enduring source of medicines and a partner in scientific progress. It advocates reframing how we think about disease in ecosystems and highlights chemistry as a practical bridge between human medicine and wildlife conservation.